Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Implantable Defibrillators Reduce Inappropriate Shocks

By HospiMedica International staff writers
Posted on 13 Apr 2011
A portfolio of new implantable cardioverter-defibrillators (ICDs) and cardiac resynchronization therapy-defibrillators (CRT-Ds) recognize life-threatening arrhythmias and deliver therapeutic shocks only when appropriate, thus enhancing patient quality of life.

The Medtronic Protecta family of ICDs and CRT-Ds feature SmartShock technology, which is comprised of six new solutions, five of which were not previously available; the Medtronic exclusive algorithms are automatically turned on when implanted, and address the industry-wide issue of inappropriate shocks. More...
They include Wavelet + PR Logic, SVT discrimination in the VF zone, and Confirmation + in Protecta devices that are designed to detect nonlethal arrhythmias. T-wave Discrimination and Lead Noise Discrimination distinguish oversensing from deadly arrhythmias and withhold shock therapy when appropriate. The Lead Integrity Alert provides advanced warning of potential lead fractures so the patient can seek medical attention, and reduces the risk of receiving an inappropriate shock.

All Protecta XT devices have OptiVol 2.0 fluid status monitoring, an update on the Medtronic-exclusive feature that measures changes in fluid build-up in heart failure patients to identify patients at risk of worsening heart failure. The implantable defibrillators also have Conexus wireless telemetry that allows patients to transmit device data to a physician's clinic from virtually anywhere via a remote monitoring system (the Medtronic CareLink Network), which serves more than 4,000 clinics and 500,000 patients in 30 countries. The Protecta family of ICDs and CRT-Ds are products of Medtronic (Minneapolis, MN, USA), and have received the European Community (CE) marking of approval.

"The Protecta family of devices addresses one of physicians' top needs--allowing them to better serve patients by providing devices that are designed to deliver a shock only when needed to save a life,” said Pat Mackin, president of the cardiac rhythm disease management business and senior vice president at Medtronic. "This new innovation is the latest example of Medtronic's 20-year leadership in shock reduction technology through product innovation backed by industry-leading clinical research.”

"With recent studies showing that up to one in five patients may experience inappropriate shocks, this new technology can significantly mitigate that concern and will have a real-world impact on my patients' lives by improving quality of life,” said Kent Volosin, MD, a cardiologist at the University of Pennsylvania (Philadelphia, USA).

Related Links:

Medtronic
University of Pennsylvania



Gold Member
12-Channel ECG
CM1200B
New
Gold Member
Handheld Blood Glucose Analyzer
STAT-Site
New
Patient Monitoring System
AlarmSense
New
Monitor/Defibrillator
Zenix
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Copyright © 2000-2026 Globetech Media. All rights reserved.